Alpha Fusion

Tokyo, Japan· Est. 2020

A Japanese biotech developing targeted alpha therapies using Astatine-211 for precise cancer treatment with minimal side effects.

alpha-fusion.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

A Japanese biotech developing targeted alpha therapies using Astatine-211 for precise cancer treatment with minimal side effects.

Oncology

Technology Platform

Targeted alpha therapy platform based on the radioisotope Astatine-211 (²¹¹At), conjugated to small molecule or peptide targeting vectors to deliver high-energy, short-range alpha radiation directly to cancer cells.

Opportunities

Significant opportunity in treating radioiodine-refractory thyroid cancer and late-stage prostate cancer, where high unmet need exists.

The unique physics of alpha particles could offer superior efficacy and safety versus beta-emitters like Lutetium-177, potentially capturing share in the growing radiopharmaceutical market.

Risk Factors

High technical and operational risk associated with manufacturing and reliable supply of the short-lived Astatine-211 radioisotope.

Clinical risk in proving superior efficacy/safety in pivotal trials, and competitive risk from established beta-emitters and other alpha-emitters like Actinium-225.

Competitive Landscape

Competes with other radiopharmaceutical companies like Novartis (Pluvicto/Lutathera), Bayer (Xofigo), and Point Biopharma in prostate cancer, and with I-131 therapies in thyroid cancer. Differentiation lies in the use of Astatine-211's alpha particles, which may offer a more potent and localized cytotoxic effect compared to beta-emitters.

More companies in Japan →